San Diego, CA -- (SBWIRE) -- 05/16/2016 -- A deadline is coming up on June 9, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) between August 8, 2012 and March 12, 2013.

Investors who purchased a significant amount of shares of Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) between August 8, 2012 and March 12, 2013, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call 858-779-1554.

The settlement proof of claim form or detailed settlement notice for the settlement in the Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-securities-class-action-lawsuit-03142013

In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is June 9, 2016. The class action administrator for this case is Analytics Consulting LLC.

The lawsuit was originally filed in the U.S. District Court for the District of Nevada against Spectrum Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between August 8, 2012 and March 12, 2013 in regards to the drug FUSILEV®. According to the complaint the plaintiff alleged on on behalf of purchasers of Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) common stock during the period between August 8, 2012 and March 12, 2013, that Spectrum Pharmaceuticals Inc and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing allegedly materially false and misleading statements between August 8, 2012 and March 12, 2013. The plaintiff claimed that between August 8, 2012 and March 12, 2013 defendants allegedly continually dismissed concerns that sales of FUSILEV would be adversely affected by increased supplies of leucovorin and allegedly concealed the impact that the increased availability of leucovorin would have on FUSILEV sales and as a result of defendants' statements, Spectrum Pharmaceuticals Inc's stock traded at artificially inflated prices between August 8, 2012 and March 12, 2013, reaching a high of $13.05 per share on September 18, 2012.

Those who purchased shares of Spectrum Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com